{
    "clinical_study": {
        "@rank": "102586", 
        "arm_group": {
            "arm_group_label": "SpaceOAR\u2122", 
            "description": "prostate cancer patient prophetically treated by SpaceOAR\u2122"
        }, 
        "brief_summary": {
            "textblock": "A treatment with SpaceOAR\u2122 hydrogel does reduce late toxicity Grad 2 and Grad 3 of radiation\n      therapy in prostate cancer patients"
        }, 
        "brief_title": "Post-marketing Surveillance Regarding Efficacy and Safety of SpaceOAR\u2122", 
        "completion_date": {
            "#text": "January 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer Patients Treated by Radiotherapy", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The degradable SpaceOAR\u2122 hydrogel establishes for the time of radiotherapy a distance\n      between the prostate and the rectum"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient is suffering from pathologically confirmed T1-T2, N0, M0 prostate\n             adenocarcinoma.\n\n          -  Patient is intended to receive radiation therapy (3D-computerized radiotherapy,\n             intensity-modulated radiotherapy, and/or brachytherapy) and this will be the first\n             prostate or pelvic radiation therapy.\n\n          -  Patient is intended to receive SpaceOAR\u2122 Gel therapy.\n\n          -  The patient is official patient of the clinical investigator in the study centre.\n\n          -  Patient agrees to fully participate in the clinical trial and give informed consent\n             in writing.\n\n        Exclusion Criteria:\n\n          -  Anatomic abnormality, physical or pathological condition precluding the implantation.\n\n          -  Failure in the wall of the perineum room (with the risk that the hydrogel escapes).\n\n          -  History of prostate surgery or local prostate cancer therapy.\n\n          -  Rectal injury before implantation of SpaceOAR\u2122 Gel or history of or active\n             inflammatory rectal disease such as Crohn's disease or ulcerative colitis.\n\n          -  History of or current perirectal or anal disease or surgery such as prolapsed or\n             bleeding haemorrhoids or fistula.\n\n          -  Compromised immune system (e.g., HIV/acquired immunodeficiency syndrome, auto\u00acimmune\n             disease or immunosuppressive therapy).\n\n          -  Platelet count, partial thromboplastin time, or white blood cell count out of normal\n             laboratory range.\n\n          -  Contraindication for safe MRI and CT scans.\n\n          -  Patient is not able to fully participate in this study including the follow-up (e.g.\n             for mental or geographical reasons, or patient is intravenous drug user or has strong\n             potential for non-compliance to medical regimes).\n\n          -  Patient is mentally unable to understand the nature, aims, or possible consequences\n             of the clinical investigation.\n\n          -  Patient has restricted legal capacity.\n\n          -  Patient did participate in another clinical investigation during the last 3 months.\n\n          -  Patient has revoked the consent."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "prostate cancer patients treated by radiotherapy and prophetically by SpaceOAR\u2122"
            }
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01999660", 
            "org_study_id": "Space-CS-01"
        }, 
        "intervention": {
            "arm_group_label": "SpaceOAR\u2122", 
            "intervention_name": "SpaceOAR\u2122 implantation", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Prostatic Neoplasms", 
            "Radiotherapy", 
            "rectal toxicity"
        ], 
        "lastchanged_date": "November 26, 2013", 
        "location": {
            "contact": {
                "email": "galalae@evk-ge.de", 
                "last_name": "Razvan Galalae, PD Dr. med.", 
                "phone": "+49 209 - 160 - 53001"
            }, 
            "facility": {
                "address": {
                    "city": "Gelsenkirchen", 
                    "country": "Germany", 
                    "state": "NRW", 
                    "zip": "45879"
                }, 
                "name": "Clinic for Radiooncology and Radiotherapy, Evangelical Clinics Gelsenkirchen"
            }, 
            "investigator": {
                "last_name": "Razvan Galalae, PD Dr. med.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "1", 
        "official_title": "Prospective National Post-marketing Surveillance for the Investigation of the Efficacy and Safety of SpaceOAR\u2122 to Maintain Space Between the Rectum and Prostate During Radiation Therapy", 
        "other_outcome": {
            "description": "feasibility of the implantation procedure will be documented by subjective description given by the investigators. this includes safety aspects.", 
            "measure": "feasibility of the implantation procedure", 
            "safety_issue": "Yes", 
            "time_frame": "1 day"
        }, 
        "overall_contact": {
            "email": "eike@aix-scientifics.com", 
            "last_name": "Eike G. Fischer, Dr.", 
            "phone": "+49 241 4500 358"
        }, 
        "overall_official": {
            "affiliation": "Clinic for Radiooncology and Radiotherapy,  Evangelical Clinics Gelsenkirchen, Germany", 
            "last_name": "Razvan Galalae, PD Dr. med.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "the rectal complication rate following the common toxicity criteria (CTC) v. 2.0", 
            "measure": "the rectal complication rate (late toxicity)", 
            "safety_issue": "Yes", 
            "time_frame": "6 months and yearly for 5 years thereafter"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01999660"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The validated Expanded Prostate Cancer Index Composite (EPIC) questionnaire in combination with the validated Short Form Health Survey (SF-12) will be used to document the influence on the quality of life (QoL).", 
            "measure": "Quality of Life", 
            "safety_issue": "No", 
            "time_frame": "6 months and for 5 years yearly thereafter"
        }, 
        "source": "CS Diagnostics GmbH", 
        "sponsors": {
            "collaborator": {
                "agency": "Aix Scientifics", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "CS Diagnostics GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "November 2013"
    }
}